Attached files

file filename
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR8.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR7.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR3.htm
10-Q - 10-Q - XENOPORT INCd700807d10q.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR20.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR27.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR10.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR5.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR26.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR21.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR16.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR14.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR13.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR15.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR19.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR23.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR11.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR12.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR4.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR18.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR1.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR17.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR24.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR22.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR2.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR32.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR31.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR30.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR28.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR29.htm
EXCEL - IDEA: XBRL DOCUMENT - XENOPORT INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR9.htm
XML - IDEA: XBRL DOCUMENT - XENOPORT INCR25.htm
EX-32.1 - EX-32.1 - XENOPORT INCd700807dex321.htm
EX-31.2 - EX-31.2 - XENOPORT INCd700807dex312.htm
EX-31.1 - EX-31.1 - XENOPORT INCd700807dex311.htm
EX-10.22 - EX-10.22 - XENOPORT INCd700807dex1022.htm
v2.4.0.8
Organization and Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2014
Organization and Summary of Significant Accounting Policies

1. Organization and Summary of Significant Accounting Policies

Nature of Operations

XenoPort, Inc., or the Company, was incorporated in the state of Delaware on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological and other disorders. The Company is currently commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States and developing its novel fumaric acid ester product candidate, XP23829, as a potential treatment for psoriasis and/or relapsing forms of multiple sclerosis, or MS. The Company’s pipeline of product candidates also includes potential treatments for patients with spasticity related to spinal cord injury and Parkinson’s disease. HORIZANT and the Company’s product candidates are prodrugs that are typically created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug. HORIZANT and each of the Company’s product candidates are orally-available, patented molecules that address potential markets with clear unmet medical needs. The Company’s facilities are located in Santa Clara, California.

On November 8, 2012, the Company reached an agreement with Glaxo Group Limited, or GSK, to terminate the Amended and Restated Development and Commercialization Agreement dated November 7, 2010, between the Company and GSK regarding HORIZANT.

Under the terms of the November 2012 termination and transition agreement, during a transition period that ended on April 30, 2013, GSK continued to exclusively commercialize, promote, manufacture and distribute HORIZANT in the United States. The Company was not eligible to receive any milestone payments from GSK and did not receive any revenue or incur any losses from GSK’s sales of HORIZANT during the transition period. GSK continued to fully fund the costs associated with the management and conduct of required post-marketing clinical studies initiated by GSK prior to the date of the termination and transition agreement. In addition, GSK provided to the Company inventory of gabapentin enacarbil in GSK’s possession that was not required for use by GSK in the manufacture of HORIZANT and related manufacturing property and equipment. In exchange for such inventory, the Company will make annual payments to GSK of $1,000,000 for six years beginning in 2016, which was recorded at its present value as “Other noncurrent liability” on the Company’s balance sheet for the periods ended March 31, 2014 and December 31, 2013 and is being accreted to its contractual value over the payment period. On May 1, 2013, the Company completed the acquisition of the HORIZANT business in accordance with the termination and transition agreement and assumed all responsibilities and associated rights for the further development, manufacturing and commercialization of HORIZANT in the United States on that date. GSK was responsible for the commercial manufacture and supply of HORIZANT during the transition period. The Company did not assume any liabilities of GSK’s HORIZANT business as of the acquisition date.

On January 29, 2014, the Company completed an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $6.00 per share. Net cash proceeds from the public offering were approximately $67,300,000, after deducting the underwriting discounts and commissions and offering expenses payable by the Company. On February 21, 2014, the underwriters exercised in full their option to purchase 1,800,000 additional shares resulting in additional net cash proceeds of approximately $10,100,000, after deducting the underwriting discounts and commissions and offering expenses payable by the Company.

Basis of Preparation

The accompanying financial statements as of March 31, 2014 and for the three months ended March 31, 2014 and 2013 are unaudited. These unaudited financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2014 and comprehensive losses for the three months ended March 31, 2014 and 2013, and cash flows for the three months ended March 31, 2014 and 2013. The Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or the Codification, is the single source of authoritative U.S. generally accepted accounting principles, or GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from these estimates. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period or any other future year. For more complete financial information, these financial statements, and the notes hereto, should be read in conjunction with the audited financial statements for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 28, 2014. The results of operations of the acquired HORIZANT business, along with the fair values of the assets acquired in the transaction, have been included in the Company’s financial statements since the May 1, 2013 acquisition date.